Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Biopharma CoHKSE:02157 -2.92%44 Days Payable is 598.15 as of Dec. 2025, which is 66% below its 10-year median of 1,764.65. GuruFocus rates HKSE:02157 with a GF Score™ of 44/100 and a GF Value™ of HK$15.69 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 704 Biotechnology companies, Lepu Biopharma Co ranks better than 85.37% on this metric.
The historical rank and industry rank for Lepu Biopharma Co's Days Payable or its related term are showing as below:
HKSE:02157'
s Days Payable Range Over the Past 10 Years
Min: 839.35 Med: 1764.65 Max: 30972.51
Current: 866.31
During the past 7 years, Lepu Biopharma Co's highest Days Payable was 30972.51. The lowest was 839.35. And the median was 1764.65.
HKSE:02157's Days Payable is ranked better than 85.37% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs HKSE:02157: 866.31
Lepu Biopharma Co's Days Payable
declined
from Dec. 2024 (790.77) to Dec. 2025 (598.15).
It may suggest that Lepu Biopharma Coaccelerated paying its suppliers.
The historical data trend for Lepu Biopharma Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02157 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Lepu Biopharma Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Biopharma Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Lepu Biopharma Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lepu Biopharma Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Biopharma Co (HKSE:02157) has a Days Payable of 598.15 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lepu Biopharma Co and its competitors. This is 66% below median its historical median of 1,764.65. Over the past decade, Lepu Biopharma Co's Days Payable has ranged from 839.35 to 30,972.51. According to the industry distribution chart, Lepu Biopharma Co ranks #103 out of 704 companies in the Biotechnology industry, placing it in the top 14.6%.
Is Lepu Biopharma Co's Days Payable too high?
Lepu Biopharma Co's current Days Payable of 598.15 is 66% below median its 10-year median of 1,764.65. Over the past 10 years, this metric has ranged from a low of 839.35 to a high of 30,972.51. The Biotechnology industry median Days Payable is 112.72. Lepu Biopharma Co's value of 598.15 is 430.7% above this industry median. Based on the distribution chart, Lepu Biopharma Co ranks #103 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lepu Biopharma Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lepu Biopharma Co ranks #103 out of 704 companies for Days Payable. This places Lepu Biopharma Co in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.72. Lepu Biopharma Co's value of 598.15 is 430.7% above this benchmark. Historically, Lepu Biopharma Co's own Days Payable has ranged from 839.35 to 30,972.51 over the past decade. While the company's 10-year median is 1,764.65 vs. the industry median of 112.72, Lepu Biopharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Biopharma Co's current Days Payable of 598.15 is 430.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lepu Biopharma Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Biopharma Co's current Days Payable is 598.15, which is 66% below median its own 10-year median of 1,764.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$15.69, compared to a current price of HK$4.65 — trading 70.4% below its estimated fair value. The current Days Payable is 598.15, which is 66% below median its 10-year median of 1,764.65 and 430.7% above the Biotechnology industry median of 112.72. Lepu Biopharma Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current Days Payable is 598.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$4.65 is trading 70.4% below its estimated GF Value™ of HK$15.69.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
Days Payable: 598.15 (66% below median its 10-year median of 1,764.65)
GF Value™: HK$15.69 vs. price of HK$4.65 (70.4% below fair value)
Industry Position: 430.7% above the Biotechnology median (#103 of 704)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score
Get the complete analysis for HKSE:02157
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
